Health Care

4390 posts
Microbiological cultures

Lumos Diagnostics surges 140% on major US contract deal

Lumos Diagnostics (ASX:LDX) has surged 140% to 7cps after inking a $420M deal for use of…
A doctor loading an old man into a scanning machine

Noxopharm gets HERACLES autoimmune trials started with first human doses

Noxopharm Ltd (ASX:NOX) has got its HERACLES trials out the gates in Week 29, dosing a preliminary patient in
Sweat

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind
Pancreatic cancer 3D illustration

OncoSil wraps up recruitment for key pancreatic cancer trial

Pancreatic cancer treatment focused OncoSil Medical's (ASX:OSL) shares stayed flat on Friday as the company revealed…
Australian currency cash

Paradigm unlocks $40M loan – and sees a 75cps price not far away

Paradigm Biopharmaceuticals (ASX:PAR) shares were up nearly +25% in morning trades as the company unveiled a loan of around
The Market Online Video

AFT Pharmaceuticals launches Combogesic IV in Canada

AFT Pharmaceuticals has “lots of exciting things happening” as FY26 begins, not least Combogesic IV launching in Canada as
The Market Online Video

With 100 enrolled and $13.8M in hand, Actinogen’s Xanamem timeline is in full swing

Actinogen Medical (ASX:ACW) has this week enrolled its 100th participant for its “pivotal” XanaMIA phase 2b/three trial for Xanamem,
MAGNIFYING GLASS

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Orthocell (ASX:OCC) shares notched upwards on Friday as the company announced its nerve repair product has…
Neurons concept

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent…
A runner who's face we can't see stopping to hold her knee.

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop – and, of course, commercialise – a